Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion type Assertion NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_head.
- NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion description "[A significantly reduced risk of NHL was associated with the homozygous TT genotype in CBS (rs234706, Ex9+33C>T) (OR = 0.51, 95 % CI 0.31-0.84), the homozygous CC genotype in MBD2 (rs603097, -2176C>T) (OR = 0.37, 95 % CI 0.17-0.79), the heterozygote AG genotype in FTHFD (rs1127717, Ex21+31A>G) (OR = 0.73, 95 % CI 0.55-0.98), and a borderline significantly reduced risk of NHL was observed for the homozygous CC genotype in MTRR (rs161870, Ex5+136T>C) (OR = 0.23, 95 % CI 0.05-1.04).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_provenance.
- NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion evidence source_evidence_literature NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_provenance.
- NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion SIO_000772 23913011 NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_provenance.
- NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion wasDerivedFrom befree-20150227 NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_provenance.
- NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_assertion wasGeneratedBy ECO_0000203 NP853585.RARm2U0SF0U52dVz0FEyBVKNoAl6phQZlrJ22NGDXWcvs130_provenance.